Boehringer Ingelheim Press Releases

New bottle for Ingelvac MycoFLEX® simplifies mixing with Ingelvac CircoFLEX®

Large scale registry shows atrial fibrillation management is suboptimal and unequal around the world

Key results from new tiotropium studies in COPD and asthma
to be presented at ERS 2012

Clinical experience with Pradaxa® crosses one million patient-years of treatment

Cost effectiveness and clinical efficacy of Pradaxa® (dabigatran etexilate) versus rivaroxaban analysed

Boehringer Ingelheim achieves further growth in first half of 2012 – difficult business environment expected for the second half of the year

Boehringer Ingelheim Biopharmaceuticals announces manufacturing agreement with Servier

Jentadueto® (linagliptin/metformin hydrochloride) tablets receive approval for the treatment of adults with Type 2 Diabetes in Europe

Boehringer Ingelheim and Funxional Therapeutics announce acquisition of Funxional’s FX125L and the somatotaxin portfolio to treat inflammation

Ilka Diester wins Boehringer Ingelheim’s FENS Award 2012 for Exceptional Research in Neuroscience

Boehringer Ingelheim pursuing health care innovation – new collaboration with Healthrageous, Inc on a digital diabetes self-management program

Boehringer Ingelheim Establishes Translational Research Collaboration with Harvard University in Areas of Unmet Medical Need

Boehringer Ingelheim announces changes to Board of Managing Directors: Joachim Hasenmaier to lead new Board Division Consumer Healthcare and Animal Health

New publication in The Lancet: Two-year study in over 1,500 patients compares Trajenta® (linagliptin) to the commonly prescribed sulphonylurea glimepiride

No significant difference in the risk of Acute Coronary Syndrome (including Myocardial Infarction) seen with Pradaxa® (dabigatran etexilate) compared to enoxaparin for VTE prevention after orthopaedic surgery

First study to evaluate alternative to warfarin for mechanical heart valve patients launched with Pradaxa® (dabigatran etexilate)

AF patients who require surgery benefit from a shorter treatment interruption on dabigatran etexilate (Pradaxa®) compared to warfarin

Boehringer Ingelheim BioXcellence:
Distinctive brand for the biopharmaceutical contract manufacturing business